Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model


BACKGROUND Today's standard treatment of advanced-stage ovarian cancer, including surgery followed by a paclitaxel-platinum-based chemotherapy, is limited in efficacy. Recently, we could show that radioimmunotherapy (RIT) with (177)Lu-labelled anti-L1 cell adhesion molecule (L1CAM) monoclonal antibody chCE7 is effective in ovarian cancer therapy. We… (More)
DOI: 10.1186/s13550-014-0054-2


5 Figures and Tables


Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.